Sharemaestro Newsreel

Why Eli Lilly Topped the Market Today

Key Points This market has a population of almost 60 million. While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.10 stocks we like better than Eli Lilly › Eli …

Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Alcon (ALC) reported $2.78 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 8%. EPS of $0.84 for the same period compares to $0.76 a year ago. The reported revenue represents a surprise of +0.58% over the Zacks Consensus …

Alcon Inc. gibt Ergebnisprognose für den im Juli 2026 endenden Monat ab; bestätigt Ergebnisprognose für das Gesamtjahr 2026

New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth

Second-quarter 2026 sales of $2.8 billion, up 8%on a reported basis, or up 7% constant currency1 (cc), versus second-quarter 2025 Returned $538 million to shareholders through dividends and share repurchases on a year-to-date basis Updated full-year guidance - raised core operating margin and core …

Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and …

Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which …

ChemoMetec enters collaboration agreement with Roche Diagnostics

Chemometec A/S ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today …

Storebrand Europe Index - announcement of prospectus

Storebrand Asset Management AS Lysaker, 10 August 2026 Storebrand hereby announces the Prospectus with Articles of Association Appendix to the Prospectus ("tillæg" relevant to Danish investors) for Storebrand Europe Index, an index aware equity fund. The fund has been accepted for listing at Nasdaq …

Lineage Cell Therapeutics Q2 Earnings Call Highlights

Key Points Interested in Lineage Cell Therapeutics, Inc.? Here are five stocks we like better. Pipeline progress: Lineage advanced preclinical programs in corneal disease, Type 1 diabetes and hearing loss, while Roche and Genentech continued optimizing surgical delivery for the lead OpRegen retinal therapy. …

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.

Key Points Few companies have a longer track record of uninterrupted dividend growth. This streak is likely to be prolonged well into the foreseeable future. While still an income stock, Johnson & Johnson is also being priced somewhat like a growth stock.10 stocks we …

Earnings Week Ahead: SMCI, CSCO, JD, PLUG, and more

[Business Person Reviewing Quarterly Report During Meeting in Office Setting] The second full week of August features a diverse earnings slate spanning AI infrastructure, semiconductors, space technology, healthcare, financials, and consumer names, with Super Micro Computer (SMCI [https://seekingalpha.com/symbol/SMCI]), Nebius (NBIS [https://seekingalpha.com/symbol/NBIS]), Cisco Systems (CSCO …

LLY Q2 Deep Dive: Key Products and Pipeline Expansion

Global pharmaceutical company Eli Lilly (NYSE:LLY)reported Q2 CY2026 results topping the market's revenue expectations , with sales up 47.7% year on year to $22.97 billion. The company's full-year revenue guidance of $86 billion at the midpoint came in 0.6% above analysts' estimates. Its non-GAAP …

Eli Lilly (LLY) Gains FDA Breakthrough Nod As Olomorasib Cancer Trial Broadens

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with …

BofA points to the Eli Lilly market that could outsize the U.S.

Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate centered on one worry: a slow start for its new obesity pill. That worry did not disappear in the second quarter, but it stopped …

Eli Lilly and Company Q2 Earnings Call Highlights

Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. Lilly reported 48% year-over-year revenue growth in Q2 2026, with MOUNJARO and ZEPBOUND generating $14.9 billion in combined sales. The company raised its full-year revenue outlook to $85 billion–$87 …

Molecular Partners AG (MOLN) Aktuelle Aktien-News

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from …

Roche Stock Jumps as Morgan Stanley Sees Drug Breakout

This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. …

Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of …

Galenica AG bestätigt Ergebnisprognose für das Jahr 2026

Eli Lilly and Company aktualisiert Ergebnisprognose für das Jahr 2026

Molecular Partners AG (MOLN) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Addex Therapeutics Ltd (ADXN) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Cosmo N.V.: Fundamentalanalyse und Finanzratings | A2AJ68 | NL0011832936

Novartis dank starkem Ergebnis auf bestem Weg, Prognose fürs Gesamtjahr zu erreichen

Cosmo N.V. bestätigt Ergebnisprognose für das Gesamtjahr 2026

Novartis: Konsens-Beat ohne Prognoseanhebung - die Pipeline muss jetzt zeigen, was sie kann

SFZN Prognose — Kursziel für 2027

TECN Prognose — Kursziel für 2027

STMN Prognose — Kursziel für 2027

LONN Prognose — Kursziel für 2027

YPSN Prognose — Kursziel für 2027

PPGN Prognose — Kursziel für 2027

BSLN Prognose — Kursziel für 2027

NWRN Prognose — Kursziel für 2027

SANN Prognose — Kursziel für 2027